About Liraglutide API
Therapeutic CategoryAnti-diabético
CAS Number
204656-20-2
API Technology
Peptides
Dose Form
Injectable
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, EUDMF, Canada DMF, Brazil DMF
Mechanism of Action
Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). Like endogenous GLP-1, liraglutide binds to and activates the GLP-1 receptor, a cell-surface receptor coupled to adenylyl cyclase activation through the stimulatory G-protein, Gs. Endogenous GLP-1 has a half-life of 1.5-2 minutes due to degradation by the ubiquitous endogenous enzymes, dipeptidyl peptidase 4 (DPP-4) and neutral endopeptidases (NEP). Unlike native GLP-1, liraglutide is stable against metabolic degradation by both peptidases and has a plasma half-life of 13 hours after subcutaneous administration. The pharmacokinetic profile of liraglutide, which makes it suitable for once-daily administration, is a result of self-association that delays absorption, plasma protein binding, and stability against metabolic degradation by DPP-4 and NEP.
GLP-1 is a physiological regulator of appetite and calorie intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation. In animal studies, peripheral administration of liraglutide resulted in the presence of liraglutide in specific brain regions regulating appetite, including the hypothalamus. Although liraglutide activated neurons in brain regions known to regulate appetite, specific brain regions mediating the effects of liraglutide on appetite were not identified in rats.
Indication
Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of
- 30 kg/m2 or greater (obese) or
- 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia)
Limitations of Use:
- Saxenda is not indicated for the treatment of type 2 diabetes
- Saxenda should not be used in combination with any other GLP-1 receptor agonist
- Saxenda should not be used with insulin
- The effects of Saxenda on cardiovascular morbidity and mortality have not been established
- The safety and efficacy of coadministration with other products for weight loss have not been established
- Saxenda has not been studied in patients with a history of pancreatitis
Related APIs
Glimepirida
Anti-diabético
Linagliptina
Anti-diabético
Liraglutida
Anti-diabético
Pioglitazona Clorhidrato
Anti-diabético
Clorhidrato De Sitagliptina
Anti-diabético
Dapagliflozina (amorfa)
Anti-diabético
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
FAQs
Treats type 2 diabetes and chronic obesity
-
Used in medications like Victoza and Saxenda to regulate insulin secretion and reduce appetite
-
Lowers blood glucose levels
Promotes weight loss
Improves glycemic control
-
Avoid inhalation and skin contact
Use protective equipment
Store in a cool, dry place, away from light
Descargo de responsabilidad
Ninguna información en este sitio web, incluyendo cualquier referencia a cualquier producto o servicio, constituye una oferta de venta ni se interpretará como tal. Los productos protegidos por patentes válidas no se ofrecen ni suministran para uso comercial. Sin embargo, en ciertos casos, a discreción exclusiva de Dr. Reddy's y sujeto a los requisitos legales locales, las cantidades de investigación de dichos productos pueden ofrecerse para fines de presentaciones regulatorias según la Sección 107A de la Ley de Patentes de la India (exención de Bolar), donde existan dichas exenciones regulatorias. Los compradores deben realizar su propia evaluación del producto o servicio, incluyendo el escenario de patentes en sus respectivos mercados, y serán responsables de todas las responsabilidades relacionadas con las patentes. Dr. Reddy's renuncia a todas las garantías, expresas o implícitas, incluyendo, entre otras, las garantías de comerciabilidad, idoneidad para un propósito particular y no infracción.